Skip to main content

Table 3 Relationship between 6MWD and same-visit biomarkers in a larger cohort of subjects with pulmonary vascular disease

From: Treatment-related biomarkers in pulmonary hypertension patients on oral therapies

Biomarkera Estimate Standard error p-value
ET-1 (N = 98) − 33.51 13.82 0.017
NTproBNP (N = 99)    
  Log(NTproBNP + 1) ≤ 5.5, per 1 unit increase − 7.02 5.83 0.23
  Log(NTproBNP + 1) > 5.5, per 1 unit increaseb    
     PAH on treatment with ERA − 4.88 16.04 0.76
     PAH on treatment with PDE5i − 41.40 42.51 0.33
     PAH on treatment with ERA + PDE5i − 42.26 10.84 0.0002
     PAH with concomitant left heart disease − 43.89 18.84 0.021
    PAH with concomitant lung disease 1.33 18.56 0.94
   CTEPH − 77.10 18.94  < .0001
RDW (N = 99) − 179.30 54.84 0.001
cGMP (N = 96) − 0.001 7.65 0.99
SNO-Hb (N = 92) − 302.57 2498.01 0.90
cGMP/NTproBNP ratio (N = 94)    
  Log(cGMP/NTproBNP + 1) ≤ 0.3, per 1 unit increase 205.01 59.11 0.0008
  Log(cGMP/NTproBNP + 1) > 0.3, per 1 unit increase 8.48 18.33 0.64
NO2 (N = 90) 1.85 5.49 0.74
SDMA (N = 97)    
  Log(SDMA + 1) ≤ 6, per 1 unit increase 37.10 36.53 0.31
  Log(SDMA + 1) > 6, per 1 unit increase − 47.93 17.84 0.008
ADMA by therapy class and comorbidities (N = 98)c    
  ADMA, PAH on treatment with ERA − 0.23 0.086 0.01
  ADMA, PAH on treatment with PDE5i − 0.035 0.11 0.75
  ADMA, PAH on treatment with ERA + PDE5i 0.098 0.086 0.26
  ADMA, PAH with concomitant left heart disease 0.10 0.10 0.32
  ADMA, PAH with concomitant lung disease − 0.20 0.093 0.031
  ADMA, CTEPH − 0.20 0.16 0.21
  1. aAll biomarkers are transformed as log(biomarker + 1) with the exception of ADMA. All models were adjusted for age
  2. bInteraction p = 0.028
  3. cInteraction p = 0.032